Searchable abstracts of presentations at key conferences in endocrinology

ea0081rc4.3 | Rapid Communications 4: Pituitary and Neuroendocrinology 1 | ECE2022

Pre-treatment GH levels and number of therapeutic interventions for acromegaly management are predictive of altered MRI bone shape and severity of arthropathy in acromegaly

Kyriakakis Nikolaos , Bowes Michael , Lynch Julie , Kingsbury Sarah R , M Orme Steve , Murray Robert D , Conaghan Philip G

Introduction: Emerging research in 3D-bone shape has provided new insights into the pathogenesis of osteoarthritis (OA). OA patients have increased subchondral bone area, associated with higher prevalence of cartilage loss. Higher B-score, a novel, machine learning-derived OA bone biomarker, is associated with increased OA symptom severity and structural progression. Arthropathy, despite being the commonest cause of morbidity amongst acromegaly patients, remains one of the und...

ea0073aep842 | Late Breaking | ECE2021

The first comprehensive study of the clinical response of a cohort of acromegalic patients with somatostatin responsive headache

Sonia Kaniuka-Jakubowska , J Levy Miles , Pal Aparna , Abeyaratne Dayakshi , Drake William , Kyriakakis Nikolaos , D Murray Robert , M Orme Steve , Gohil Shailesh , Brook Antonia , Leese Graham , Márta Korbonits , Wass John

It is known that acromegaly may be associated with headache as a significant co-morbidity. Amongst all acromegaly headache patients, there is a unique group with specific types of severe headache that fail to improve despite acromegaly therapy and are resistant to conventional analgesics, however, immediately respond to subcutaneous short-acting (SA) somatostatin analogue (SSA) treatment. We have surveyed 8 tertiary specialist UK centres and identified 18 patients (6 females) ...